Shots:

• Atreca to receive up front and retain rights to develop Abs included in the collaboration with Merck while Merck will get a right-of-first negotiation- if Atreca out-licenses its one or more Abs therapies
• Following target identification- both the companies have the right to advance therapeutic candidates against the targets identified under the collaboration in the exchange of development & commercial milestones payable by either party
• Atreca’s lead candidate ATRC-101 has the potential to address unmet medical needs of cancer patients with its anticipated initiation of P-Ib study for a solid tumor in H1’20

Click here to­ read full press release/ article 

Ref: GlobeNewswire | Image: Merck